Mesenchymal Stem Cells Drive Cardiac Stem Cell Chemotaxis, Proliferation, and Phenotype via CXCR4 and cKit Signaling
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Heart failure remains one of the greatest human health threats, accounting for nearly one third of all deaths within the United States and with global penetrance.1 Ischemic cardiomyopathy is a major contributor to heart failure (HF) with massive numbers of cardiomyocytes lost as a result of myocardial infarction. Post myocardial infarction, ongoing apoptosis is a significant contributor to heart failure progression regardless of pathogenesis, exacerbating the loss of viable myocardium. With the discovery that cardiac regeneration can occur, cell therapy emerged as a novel and safe approach to cardiac repair and regeneration.
Article, see p 921
Historically, cardiac regeneration research has focused on delivering stem cells of mesenchymal and hematopoietic origin to the heart. Myocardial residence times of delivered cells have been shown to be discouragingly short, casting doubt on their regenerative potential in the heart. Excitement levels remain high because (1) mesenchymal stem cells (MSCs) express beneficial paracrine factors, (2) resident cardiac stem cells (CSCs) have cardiomyogenic potential,2 (3)endogenous cKit+ resident CSCs have multiple lineage potential, (4) MSC or CSC delivery to the failing heart results in improved cardiac function, angiogenesis, and detection of CSCs with cardiomyocyte phenotypes,3 (5) MSCs communicate with …